Physician profile
Ignacio Cendan
NPI 1194711861
$140,298.32
in general payments reported to CMS, 2019-2025
40 companies · $2,918 in 2025
The $2,918 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $12K · 2021: $28K · 2022: $34K · 2023: $30K · 2024: $12K · 2025: $2,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Food and Beverage: $9,148 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,075.00 |
| Food and Beverage | $9,148.45 |
| Education | $217.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $124,640.79 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $2,768.39 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,501.19 | 2019-2025 | Ofev, Jascayd, Spiriva |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $1,529.84 | 2019-2024 | Opsumit, Uptravi |
| Insmed, INC. | $840.51 | 2019-2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $780.52 | 2020-2025 | Acthar |
| Genzyme Corporation | $678.88 | 2019-2025 | |
| Abbvie INC. | $435.41 | 2021-2023 | Avycaz, Dalvance |
| Mylan Specialty L.P. | $434.86 | 2019-2024 | Yupelri |
| Ethicon INC. | $413.30 | 2023-2024 | Monarch Platform |
| Regeneron Healthcare Solutions, INC. | $335.43 | 2021-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $296.60 | 2019-2025 | |
| Verona Pharma, INC. | $278.53 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $249.17 | 2021-2024 | Glassia |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $246.02 | 2023-2024 | Opdivo |
| Genentech USA, INC. | $234.78 | 2019 | |
| Inspire Medical Systems, INC. | $204.13 | 2024-2025 | Inspire |
| Baxter Healthcare | $199.22 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System, Hillrom - Life 2000 Ventilation System |
| Philips North America LLC | $191.64 | 2021-2023 | |
| United Therapeutics Corporation | $159.66 | 2022-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $148.78 | 2022-2025 | Tezspire |
| Paratek Pharmaceuticals, INC. | $141.76 | 2020-2024 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $122.99 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $121.36 | 2019 | |
| Inogen, INC. | $96.74 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Sanofi-Aventis U.S. LLC | $94.95 | 2024 | |
| Merck Sharp & Dohme LLC | $91.47 | 2025 | Winrevair |
| Advanced Respiratory, INC | $68.71 | 2021 | |
| Medtronic, INC. | $59.21 | 2022-2023 | Illumisite |
| Allergan, INC. | $58.37 | 2019-2020 | |
| Lilly USA, LLC | $57.34 | 2022-2025 | Zepbound, Mounjaro |
| Viatris Specialty LLC | $46.01 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $41.06 | 2019-2021 | |
| Electromed, INC. | $33.90 | 2019 | |
| Itamar Medical INC | $28.02 | 2025 | Watchpatone |
| Liquidia Technologies, INC. | $23.28 | 2025 | Yutrepia |
| Optinose US, INC. | $16.54 | 2021 | |
| Hikma Pharmaceuticals USA | $16.11 | 2024 | Ryaltris |
| Cmp Pharma, INC. | $12.85 | 2023 | Tadliq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ignacio Cendan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.